Shares of Glenmark Pharma declined by 2.12% to trade at Rs 2,172.10 in Tuesday's session. The stock is among the top losers on Nifty Midcap 150. At 10:02 am, the stock price reflected a notable ...

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The stock is up 57.28% in last one year as compared to a 1.88% jump in NIFTY and a 7.85% jump in ...

We are just trying to regroup. One wrong move takes you back by four or five years,' Glenn Saldanha said, emphasising caution ...

But now, an Indian company has delivered a promising innovative anti-cancer drug molecule to deep-pocketed Big Pharma for ...

An analyst from Anand Rathi said that BHEL is encountering strong resistance in the Rs 265–270 zone, which coincides with its ...

Glenmark Pharmaceuticals receives FDA warning letter for Indore facility, commits to resolving compliance issues promptly.

Glenmark’s progress with a cancer treatment shows the potential of Indian pharma to move from generics to drug discovery. With tech-enabled therapies evolving fast, new inflection points spell a ...

In an official filing, the company stated that it does not anticipate the warning letter will disrupt supply chains or affect ...

In the Nifty 50, Hero Motor and Sun Pharma led the gains of the index. Eicher Motors and IndusInd Bank were also trading higher.

The ₹3,395 crore IPO of the Bengaluru-based Anthem Biosciences Ltd will open to the public today and close on July 16.

After two weeks of losses, the Nifty heads into a very important week amidst a rise in global trade tensions. However, the ...